| pubmed-article:8118826 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8118826 | lifeskim:mentions | umls-concept:C0007634 | lld:lifeskim |
| pubmed-article:8118826 | lifeskim:mentions | umls-concept:C0162638 | lld:lifeskim |
| pubmed-article:8118826 | lifeskim:mentions | umls-concept:C1552114 | lld:lifeskim |
| pubmed-article:8118826 | lifeskim:mentions | umls-concept:C0017262 | lld:lifeskim |
| pubmed-article:8118826 | lifeskim:mentions | umls-concept:C1268567 | lld:lifeskim |
| pubmed-article:8118826 | lifeskim:mentions | umls-concept:C0205263 | lld:lifeskim |
| pubmed-article:8118826 | lifeskim:mentions | umls-concept:C2911684 | lld:lifeskim |
| pubmed-article:8118826 | lifeskim:mentions | umls-concept:C0185117 | lld:lifeskim |
| pubmed-article:8118826 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:8118826 | pubmed:dateCreated | 1994-4-7 | lld:pubmed |
| pubmed-article:8118826 | pubmed:abstractText | Eight protein tyrosine kinase inhibitors with in vitro epidermal growth factor receptor kinase 50% inhibitory concentration values ranging from 0.043 to 22 microM were studied for their ability to inhibit the growth of the murine interleukin-3 (IL-3) dependent myeloid 32D cl3(G) cell line and, a subclone (LG7) transformed to IL-3 independent growth by retroviral transduction and expression of the chronic myelogenous leukemia-associated protein tyrosine kinase p210bcr/abl. Cell proliferation 50% inhibitory concentration values ranged from 4 to 250 microM, and one compound was not inhibitory at 500 microM. The dose-cell proliferation curves were remarkably similar for parental 32D cl3(G) cells + IL-3 and LG7 +/- IL-3, and reversion of LG7 cells to IL-3 dependence was not observed, suggesting that none of the compounds tested could selectively inhibit p210bcr/abl. However, 6 compounds induced the appearance of a 200-base pair nucleosomal DNA ladder characteristic of apoptosis at 24 h in parental 32D cl3(G) cells + IL-3, which mimicked the effects of IL-3 withdrawal alone, but not in similarly growth arrested LG7 cells that eventually developed a necrotic pattern of DNA fragmentation. These studies suggest that the expression of p210bcr/abl can suppress apoptotic signal transduction and that this may contribute to the development of the myeloid hyperplasia that occurs in chronic phase chronic myelogenous leukemia. | lld:pubmed |
| pubmed-article:8118826 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8118826 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8118826 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8118826 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8118826 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8118826 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8118826 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8118826 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:8118826 | pubmed:issn | 0008-5472 | lld:pubmed |
| pubmed-article:8118826 | pubmed:author | pubmed-author:TimmMM | lld:pubmed |
| pubmed-article:8118826 | pubmed:author | pubmed-author:HudsonA TAT | lld:pubmed |
| pubmed-article:8118826 | pubmed:author | pubmed-author:LaneuvillePP | lld:pubmed |
| pubmed-article:8118826 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8118826 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:8118826 | pubmed:volume | 54 | lld:pubmed |
| pubmed-article:8118826 | pubmed:geneSymbol | neo | lld:pubmed |
| pubmed-article:8118826 | pubmed:geneSymbol | bcr-abl | lld:pubmed |
| pubmed-article:8118826 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8118826 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8118826 | pubmed:pagination | 1360-6 | lld:pubmed |
| pubmed-article:8118826 | pubmed:dateRevised | 2009-11-19 | lld:pubmed |
| pubmed-article:8118826 | pubmed:meshHeading | pubmed-meshheading:8118826-... | lld:pubmed |
| pubmed-article:8118826 | pubmed:meshHeading | pubmed-meshheading:8118826-... | lld:pubmed |
| pubmed-article:8118826 | pubmed:meshHeading | pubmed-meshheading:8118826-... | lld:pubmed |
| pubmed-article:8118826 | pubmed:meshHeading | pubmed-meshheading:8118826-... | lld:pubmed |
| pubmed-article:8118826 | pubmed:meshHeading | pubmed-meshheading:8118826-... | lld:pubmed |
| pubmed-article:8118826 | pubmed:meshHeading | pubmed-meshheading:8118826-... | lld:pubmed |
| pubmed-article:8118826 | pubmed:meshHeading | pubmed-meshheading:8118826-... | lld:pubmed |
| pubmed-article:8118826 | pubmed:meshHeading | pubmed-meshheading:8118826-... | lld:pubmed |
| pubmed-article:8118826 | pubmed:meshHeading | pubmed-meshheading:8118826-... | lld:pubmed |
| pubmed-article:8118826 | pubmed:meshHeading | pubmed-meshheading:8118826-... | lld:pubmed |
| pubmed-article:8118826 | pubmed:meshHeading | pubmed-meshheading:8118826-... | lld:pubmed |
| pubmed-article:8118826 | pubmed:meshHeading | pubmed-meshheading:8118826-... | lld:pubmed |
| pubmed-article:8118826 | pubmed:year | 1994 | lld:pubmed |
| pubmed-article:8118826 | pubmed:articleTitle | bcr/abl expression in 32D cl3(G) cells inhibits apoptosis induced by protein tyrosine kinase inhibitors. | lld:pubmed |
| pubmed-article:8118826 | pubmed:affiliation | Department of Medicine, McGill University, Royal Victoria Hospital, Montreal, Quebec, Canada. | lld:pubmed |
| pubmed-article:8118826 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8118826 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8118826 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8118826 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8118826 | lld:pubmed |
